PCD Treatments Database

Research and evidence on treatments studied for Primary Ciliary Dyskinesia

Medical Disclaimer: The information provided on this page is for educational and informational purposes only. It is not intended as medical advice and should not be used as a substitute for professional medical care or advice. Always consult with a qualified healthcare provider regarding any medical questions or conditions. CurePCD does not endorse any specific treatments or therapies.
Medications
Antibiotics
Therapies
Testing
Diagnosis
Supplements

Medications Studied in PCD

Azithromycin 3 studies

Description
Azithromycin as an oral antibiotic can be used as an anti-inflammatory to help with PCD.
Research Studies
2023
Azithromycin promotes proliferation, and inhibits inflammation in nasal epithelial cells in primary ciliary dyskinesia
Zofia Varenyiova + others
Nature
2020
Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA)
Helene E Kobbernagel + others
The Lancet. Respiratory Medicine
2018
Prophylactic azithromycin in patients with primary ciliary dyskinesia
Alix Massiot + others
European Respiratory Journal

Antibiotics Studied in PCD

No treatments have been added to this category yet.

Therapies Studied in PCD

No treatments have been added to this category yet.

Testing Studied in PCD

No treatments have been added to this category yet.

Diagnosis Studied in PCD

No treatments have been added to this category yet.

Supplements Studied in PCD

N-Acetyl Cysteine (NAC) 10 studies

Description
N-Acetyl Cysteine (NAC) is a supplement with potential anti-bacterial properties when ingested orally.
Research Studies
2024
Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis
L. Jayaram + others
Pulmonary Pharmacology & Therapeutics
2023
N-acetylcysteine (NAC) attenuates quorum sensing regulated phenotypes in Pseudomonas aeruginosa PAO1
Emília Maria França Lima + others
Heliyon
2022
Activity of N-Acetylcysteine Alone and in Combination with Colistin against Pseudomonas aeruginosa Biofilms and Transcriptomic Response to N-Acetylcysteine Exposure
Felice Valzano + others
Microbiol Spectr.
2021
N-Acetyl-l-cysteine-Loaded Nanosystems as a Promising Therapeutic Approach Toward the Eradication of Pseudomonas aeruginosa Biofilms
Rita M. Pinto + others
American Chemical Society
2019
Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial
Qian Qi + others
Respir Res.
2016
N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions
Eduardo P Amaral + others
BMC Microbiology
2015
. The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection
Marianne Skov + others
J Cyst Fibros.
2010
N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa
Tiemei Zhao + others
BMC Microbiology
2006
High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis
Rabindra Tirouvanziam + others
Proc Natl Acad Sci U S A.
1988
The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia
G Stafanger + others
The European respiratory journal
Show 2 More Studies
Important Note: This information database summarizes published research findings and does not constitute medical advice. The treatment of PCD is complex and should be managed by healthcare professionals with expertise in the condition. Each patient's situation is unique and requires individualized care. Please consult with your healthcare provider before making any changes to your treatment regimen.